Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bertram Pitt

Showing results (531-540 of 688) with videos related to

Pageof 69
Sort By:
Circulation. Heart Failure|December 21, 2018
Cardiac Troponin I and Risk of Cardiac Events in Patients With Heart Failure and Preserved Ejection FractionPeder L Myhre, Eileen O'Meara, Brian L Claggett, et al.
European Journal of Heart Failure|October 26, 2017
Influence of ejection fraction on cause-specific mortality in heart failure with preserved ejection fractionNavkaranbir S Bajaj, Brian Claggett, Eldrin F Lewis, et al.
Journal of Cardiac Failure|August 6, 2013
Biomarker-guided therapies in heart failure: a forum for unified strategiesMona Fiuzat, Christopher M O'Connor, Francois Gueyffier, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|October 17, 2022
Finerenone efficacy in patients with chronic kidney disease, type 2 diabetes and atherosclerotic cardiovascular diseaseGerasimos Filippatos, Stefan D Anker, Bertram Pitt, et al.
European Heart Journal|May 1, 2016
A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney diseaseGerasimos Filippatos, Stefan D Anker, Michael Böhm, et al.
Lancet (London, England)|September 4, 2024
Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysisPardeep S Jhund, Atefeh Talebi, Alasdair D Henderson, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|December 1, 2021
Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE resultsRajiv Agarwal, Stefan D Anker, Gerasimos Filippatos, et al.
European Journal of Heart Failure|November 22, 2016
Impact of eplerenone on cardiovascular outcomes in heart failure patients with hypokalaemiaPatrick Rossignol, Nicolas Girerd, George Bakris, et al.
American Heart Journal|August 9, 2005
Comparison of losartan and captopril on heart failure-related outcomes and symptoms from the losartan heart failure survival study (ELITE II)Marvin A Konstam, James D Neaton, Philip A Poole-Wilson, et al.
Science Translational Medicine|February 8, 2023
Metabolic reprogramming by immune-responsive gene 1 up-regulation improves donor heart preservation and functionIenglam Lei, Wei Huang, Pierre Emmanuel Noly, et al.
Pageof 69

Showing results (531-540 of 688) with videos related to

Sort By:
Pageof 69
Circulation. Heart Failure|December 21, 2018
Cardiac Troponin I and Risk of Cardiac Events in Patients With Heart Failure and Preserved Ejection FractionPeder L Myhre, Eileen O'Meara, Brian L Claggett, et al.
European Journal of Heart Failure|October 26, 2017
Influence of ejection fraction on cause-specific mortality in heart failure with preserved ejection fractionNavkaranbir S Bajaj, Brian Claggett, Eldrin F Lewis, et al.
Journal of Cardiac Failure|August 6, 2013
Biomarker-guided therapies in heart failure: a forum for unified strategiesMona Fiuzat, Christopher M O'Connor, Francois Gueyffier, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|October 17, 2022
Finerenone efficacy in patients with chronic kidney disease, type 2 diabetes and atherosclerotic cardiovascular diseaseGerasimos Filippatos, Stefan D Anker, Bertram Pitt, et al.
European Heart Journal|May 1, 2016
A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney diseaseGerasimos Filippatos, Stefan D Anker, Michael Böhm, et al.
Lancet (London, England)|September 4, 2024
Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysisPardeep S Jhund, Atefeh Talebi, Alasdair D Henderson, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|December 1, 2021
Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE resultsRajiv Agarwal, Stefan D Anker, Gerasimos Filippatos, et al.
European Journal of Heart Failure|November 22, 2016
Impact of eplerenone on cardiovascular outcomes in heart failure patients with hypokalaemiaPatrick Rossignol, Nicolas Girerd, George Bakris, et al.
American Heart Journal|August 9, 2005
Comparison of losartan and captopril on heart failure-related outcomes and symptoms from the losartan heart failure survival study (ELITE II)Marvin A Konstam, James D Neaton, Philip A Poole-Wilson, et al.
Science Translational Medicine|February 8, 2023
Metabolic reprogramming by immune-responsive gene 1 up-regulation improves donor heart preservation and functionIenglam Lei, Wei Huang, Pierre Emmanuel Noly, et al.
Pageof 69